Navigation Links
FDA Approves Longer Duration Efficacy and Safety for EUFLEXXA®
Date:10/21/2011

nfection around the injection site.

EUFLEXXA is only for injection into the knee preformed by a qualified doctor or healthcare professional. After you receive this injection you may need to avoid physical activities for 48 hours such as jogging, tennis, heavy lifting or standing on your feet for more than one hour at a time. The safety and efficacy of EUFLEXXA has not been established in pregnant women, women who are nursing, or in children less than 18 years of age.

The most common adverse events and symptoms that occurred during clinical studies of EUFLEXXA were: pain in the knee or at the injection site and stiffness, swelling or warmth in or around the knee.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, LYSTEDA® (tranexamic acid tablets), FIRMAGON® (degarelix for injection), and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

All registered trademarks above are owned by Ferring B.V.

CONTACT:
Christy Maginn
202-530-4730
christy.maginn@bm.com


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... N.J. , March 5, 2015 Soligenix, ... stage biopharmaceutical company committed to developing products that address ... and biodefense, announced today that its President and Chief ... give a corporate presentation at the 27 th ... , on Tuesday, March 10, 2015 at 1:00 ...
(Date:3/5/2015)... March 5, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Annual ROTH Conference, to be held March 8-11, 2015, ... James Sapirstein , Chief Executive Officer, will ... live presentation and will be available to participate in ...
(Date:3/5/2015)... Hitachi Medical Systems Europe ... *    at ECR 2015 - the open ... a benchmark for patient-centric care. The new features of ... optimizing workflow management and costs. OASIS demonstrates the high ... imaging in Neurology, Orthopaedics, Paediatrics, Oncology, Vascular and General ...
Breaking Medicine Technology:Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3ContraVir to Present at 27th Annual ROTH Conference 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 3
... Repro-Med Systems, Inc., (REPR.PK) announced today that it has ... to begin U.S. marketing of its new Subcutaneous Needle ... Flo™ RMS Subcutaneous Needle Sets.  The needle sets are ...  The needle sets have previously been approved and available ...
... Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced ... Stock Market LLC (the "NASDAQ"), indicating that CTI has regained ... , NASDAQ Listing Rule 5550(a)(2)) for continued listing on ... compliance with all applicable listing standards. Therefore, the scheduled ...
Cached Medicine Technology:FDA Approves Marketing of RMS Subcutaneous Needle Sets 2FDA Approves Marketing of RMS Subcutaneous Needle Sets 3Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule 2
(Date:3/5/2015)... 05, 2015 TCS Healthcare Technologies (TCS), ... the population health management arena, is pleased to announce ... software, ACUITY Advanced Care™ (ACUITY) version 7.20. The session ... and the advantages of automation. , The webinar, scheduled ... be led by Jeff Frater, RN, BSN, Director of ...
(Date:3/5/2015)... PA (PRWEB) March 05, 2015 ... leader in healthcare communications and education, announced today ... (AMP), the nation’s only medical conference designed ... limb ischemia and lower limb amputation due to ... growing family of innovative, evidence-based publications and CME ...
(Date:3/5/2015)... Los Angeles, Calif. (PRWEB) March 05, 2015 ... company and the leader in the natural products coffee ... Coffee at Natural Products Expo West in Anaheim, Calif. ... Califia’s home café concept, Califia Café, which democratizes the ... drinkers all the ingredients they need to become their ...
(Date:3/5/2015)... Frisco, TX (PRWEB) March 05, 2015 ... Convention Center in Fort Worth, Texas April 9-11th ... and wellness company providing personalized nutrition. IDLife ... core product, IDNutrition. This customized approach to ... research that begins with a free HIPAA compliant ...
(Date:3/5/2015)... March 05, 2015 For PASCHA Chocolate, ... most essential ingredients, the robust flavor of the cacao ... PASCHA Chocolate is free from peanuts, nuts, dairy, ... PASCHA's offering March 6th- 8th at Expo West., ... PASCHA Chocolate has broken new ground with their New ...
Breaking Medicine News(10 mins):Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2Health News:PASCHA Allergen Free Organic Chocolate to Appear at Natural Products Expo West March 6-8, 2015 2
... WOODCLIFF LAKE, N.J., Dec. 12 Par Pharmaceutical Companies, Inc. ... Veronica A. Lubatkin, executive vice president and chief financial officer, ... , , Lawrence A. ... vice president of finance and will assume the role of ...
... September 8, 2008, TooBusyWorking was launched as a next-generation ... openings from all major employers onto a single Web ... than CareerBuilder, HotJobs, Nurse.com and Monster combined. , ... large number of job openings, each listing on TooBusyWorking ...
... can be achieved. A supplement published in Malaria ... many aspects of the research agenda for global malaria ... progress that has been made in the development of ... prevention. Elimination requires a different vaccine strategy, since success ...
... Terumo Corporation and Terumo,s,subsidiary, Terumo Cardiovascular Systems ... agreement to settle all outstanding litigation with,Maquet Cardiovascular, ... lawsuits pending,in which each claims the other has ... and devices used in endoscopic vessel harvesting. ...
... /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS ... of the Toronto Stock Exchange, today commented on the ... is not aware of any reason for the recent ... Fee Act (PDUFA) action date for its once-daily formulation ...
... To protect the security of online file access from Internet fraud, ... its existing program Vetted QuickBase. , ... Raleigh, NC ... further protects its online file access from web fraud ...
Cached Medicine News:Health News:Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer 2Health News:Malaria Journal supplement evaluates steps toward elimination 2Health News:Labopharm Comments on Recent Trading Activity 2Health News:To Further Combat Internet Fraud, Heightened Security Levels are Implemented by Vetted International 2Health News:To Further Combat Internet Fraud, Heightened Security Levels are Implemented by Vetted International 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: